Emerging resistance to empiric antimicrobial regimens for pediatric bloodstream infections in Malawi (1998-2017)

Citation for published version:
Iroh Tam, P-Y, Musicha, P, Kawaza, K, Cornick, J, Denis, B, Freyne, B, Everett, D, Dube, Q, French, N, Feasey, N & Heyderman, R 2018, 'Emerging resistance to empiric antimicrobial regimens for pediatric bloodstream infections in Malawi (1998-2017)', Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciy834

Digital Object Identifier (DOI):
10.1093/cid/ciy834

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Clinical Infectious Diseases

Publisher Rights Statement:
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. Supplementary data

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Emerging Resistance to Empiric Antimicrobial Regimens for Pediatric Bloodstream Infections in Malawi (1998–2017)

Pui-Ying Iroh Tam,1,2,4,a Patrick Musicha,1,3,a,b Kondwani Kawaza,3 Jenifer Cornick,1,4 Brigitte Denis,1 Bridget Freyne,1,4 Dean Everett,1,5 Queen Dub,1,5 Neil French,1,3 Nicholas Feasey,1,2 and Robert Heyderman1,3,a

1Malawi-Liverpool Wellcome Trust, Institute of Infection and Global Health, University of Liverpool, 2Liverpool School of Tropical Medicine, United Kingdom; 3University of Malawi College of Medicine, Blantyre; and 4Institute of Infection and Global Health, University of Liverpool, 5The Queens Medical Research Institute, University of Edinburgh, and 6University College London, United Kingdom

Background. The adequacy of the World Health Organization's Integrated Management of Childhood Illness (IMCI) antimicrobial guidelines for the treatment of suspected severe bacterial infections is dependent on a low prevalence of antimicrobial resistance (AMR). We describe trends in etiologies and susceptibility patterns of bloodstream infections (BSI) in hospitalized children in Malawi.

Methods. We determined the change in the population-based incidence of BSI in children admitted to Queen Elizabeth Central Hospital, Blantyre, Malawi (1998–2017). AMR profiles were assessed by the disc diffusion method, and trends over time were evaluated.

Results. A total 89 643 pediatric blood cultures were performed, and 10 621 pathogens were included in the analysis. Estimated minimum incidence rates of BSI for those ≤5 years of age fell from a peak of 11.4 per 1000 persons in 2002 to 3.4 per 1000 persons in 2017. Over 2 decades, the resistance of Gram-negative pathogens to all empiric, first-line antimicrobials (ampicillin/penicillin, gentamicin, ceftriaxone) among children ≤5 years increased from 3.4% to 30.2% (P < .001). Among those ≤60 days, AMR to all first-line antimicrobials increased from 7.0% to 67.7% (P < .001). Among children ≤5 years, Klebsiella spp. resistance to all first-line antimicrobial regimens increased from 5.9% to 93.7% (P < .001).

Conclusions. The incidence of BSI among hospitalized children has decreased substantially over the last 20 years, although gains have been offset by increases in Gram-negative pathogens' resistance to all empiric first-line antimicrobials. There is an urgent need to address the broader challenge of adapting IMCI guidelines to the local setting in the face of rapidly-expanding AMR in childhood BSI.

Keywords. antimicrobial resistance; pediatric; neonatal; sepsis; Gram-negative.

Sepsis accounted for half a million child deaths globally in 2000, and had the lowest decline of all the top 7 causes of death in this population by 2015, with only a 25% decrease compared to other leading causes, such as pneumonia (47%), diarrhea (57%) and measles (85%) [1]. In 2015, sepsis and other infectious conditions of the newborn accounted for 7% of all deaths worldwide among children under 5 years of age [1]. Empiric, first-line antimicrobial treatment for sick infants in the World Health Organization's (WHO’s) Integrated Management of Childhood Illness (IMCI) guidelines consists of penicillin/ampicillin with gentamicin, or ceftriaxone (as is practiced in Malawi). At our center in Malawi, ceftriaxone has been available since 2001, was introduced as an empiric antibiotic for neonatal meningitis in 2009 [2], and has been used as the first-line treatment for suspected neonatal sepsis since 2013 [3]. Pediatric departmental guidelines recommend the use of penicillin and gentamicin for suspected sepsis or ceftriaxone for suspected meningitis, typhoid fever, and non-typhoidal Salmonella (NTS). These recommendations are based on sparse data from low- and middle-income countries (LMICs), and are intended to be adjusted to local susceptibility patterns so that “appropriate therapy [can be given] for an identified bacterial cause” [4]. This can be challenging in LMICs, where a paucity of diagnostic microbiology facilities [5] limits the ability of clinicians to optimize empiric therapy.

Child mortality in Malawi has been falling in the last 20 years as a consequence of multiple interventions, including better nutrition, new vaccines (including the H. influenzae type B conjugate vaccine in 2002 and S. pneumoniae conjugate...
vaccine in 2011), rapid roll-out of human immunodeficiency virus prevention and care, and improvements in malaria control [6–11]. A growing problem has been increasing rates of antimicrobial resistance (AMR) [12, 13], which may be caused and compounded by inappropriate prescribing, under-dosing, and nonadherence to guidelines [14, 15]. There is a scarcity of high-quality bloodstream-infection (BSI) surveillance data to inform policy change. We have previously documented the expansion of extended-spectrum beta-lactamase (ESBL) and fluoroquinolone resistance among common Gram-negative pathogens, as well as the emergence of methicillin-resistant Staphylococcus aureus in BSI [12], but did not explore this in detail in the population ≤5 years, where the impact may be greatest. This study reviews the pediatric surveillance data collected over 2 decades at an urban district hospital and tertiary referral center in Malawi. We describe trends in the etiology and the prevalence of AMR amongst BSI isolates cultured from hospitalized children. Finally, we assess the adequacy of current IMCI guidelines in this setting.

METHODS

Setting
Queen Elizabeth Central Hospital (QECH) in Blantyre, Malawi, is a 1250-bed, government-funded teaching hospital providing free medical care, and is the main teaching hospital of the University of Malawi College of Medicine. It is the referral center for the southern half of the country and serves as the district hospital for the urban Blantyre area (estimated population 920,000 in 2016). The pediatric department admits 20,000–30,000 children a year, with 65,000–80,000 seen annually in the pediatric Accident and Emergency unit. Total numbers of pediatric hospital admissions have remained broadly constant over the study period (Supplementary Table 1). Similarly, the neonatal unit admits 3500 neonates a year, and these numbers have remained consistent over the past decade, since admission data were first collected.

Study Design
We reviewed blood culture data collected at QECH over 20 consecutive years (1998–2017; Supplementary Figure 1). Blood culture sampling in children was obtained from any pediatric patient with a clinical suspicion of sepsis, severe sepsis, or septic shock [16]; with a non-focal febrile illness and a negative test for malaria; or who remained febrile despite empiric antimicrobial treatment. Sampling followed set departmental guidelines, which have remained unchanged over the period of surveillance. Repeat blood cultures were not routinely done in the setting of a positive result. Precise individual- or population-based antimicrobial usage data for the surveillance period were not available. An analysis of microbiological surveillance data was approved by the University of Malawi College of Medicine Research Ethics Committee (P08/14/1614).

Microbiology
Routine, quality-assured, diagnostic blood culture services have been provided for children admitted to QECH by the Malawi-Liverpool-Wellcome Trust Clinical Research Programme since 1998. Among children, 1–2 mLs of blood were obtained, where possible, for culture under aseptic conditions and were inoculated into a single aerobic bottle (BacT/Alert, bioMérieux, Marcy-L’Etoile, France). All lab data over the study period were collected for children ≤5 years, including young infants <60 days. Further clinical data was unavailable. Where possible, all duplicates were removed.

The automated BacT/Alert system (bioMérieux, France) has been used to incubate samples since 2000. Before then, manual cultures were used, as previously described [17], with organism identification using Analytical Profile Index (Biomérieux). Staphylococci were identified by slide coagulase, beta-hemolytic Streptococci by Lancefield antigen testing, and Salmonellae by serotyping, according to the White-Kauffmann-Le Minor scheme. Haemophilus influenzae were typed using type B antisera. Aerococcus spp., Alcaligenes spp., alpha-hemolytic streptococci (other than S. pneumoniae), Bacillus spp., Corynebacteria, Micrococcus spp., coagulase-negative staphylococci, unidentified gram-positive rods, and the Rhizobium spp. that form part of the normal skin or oral flora were considered contaminants.

In Malawi, first-line antimicrobial regimens for the treatment of pediatric and neonatal BSI include ampicillin/penicillin with gentamicin, or ceftriaxone. Antimicrobial susceptibility was determined by the disc diffusion method (Oxoid, United Kingdom), following the current version of the British Society of Antimicrobial Chemotherapy’s guidelines (http://www.bsac.org.uk). Intermediate susceptibility (with the exception of S. pneumoniae) was regarded as resistant. Methicillin resistance in S. aureus was inferred by resistance to cefoxitin, which replaced oxacillin resistance testing in 2010. For S. pneumoniae, reduced susceptibility to penicillin was detected by oxacillin disc, with resistance defined as a minimum inhibitory concentration >2 µg/mL. Formal minimum inhibitory concentration testing was not done. Since 2007, gram-negative isolates have been screened for their ESBL-producing status using a cefpodoxime disc. Prior to this, the ESBL-producing status was inferred based on any resistance to ceftriaxone.

Statistical Analysis
We estimated minimum annual incidence rates, expressed as incidences per 1000 age-specific person years, by dividing the number of bacteremia cases per year by the mid-year population and multiplying by 1000. We modeled the observed annual case frequencies and then estimated incidences by dividing the predicted case frequencies by the mid-year populations. Age-stratified population estimates for
urban Blantyre for the years 1998–2017 were obtained from the 1998 and 2008 National Population Projections by the National Statistical Office (http://www.nsomalawi.mw). We used yearly values for children ≤5 years, but when there were low numbers of cases, including for young infants ≤60 days, we combined data into 5-year periods to enable comparisons. We followed the WHO definition of young infants as ≤60 days [4] and defined early-onset neonatal BSI as <7 days and late-onset neonatal BSI as 7–90 days. We used negative, binomial regression models to test for linear trends in incidence rates and the Cochran-Armitage test to detect trends in AMR rates. All statistical analyses were performed using R Statistical Package version 3.3.2 for MacOS (R Core Team, http://www.r-project.org).

RESULTS

Between 1998–2017, a total of 89,643 blood cultures from pediatric patients were identified. Of these, 10,621 pathogenic bacteria were identified from children ≤5 years, including 2,898 from young infants ≤60 days.

Incidence Rates

Minimum incidence rates of pediatric BSI decreased significantly over 2 decades (Figure 1), falling from a peak of 11.4 per 1000 persons in 2002 for children ≤5 years to 3.4 per 1000 persons in 2017 (overall decreasing trend, P < .001). For young infants, minimum incidence rates decreased from 8.7 per 1000 persons in 2000 to 1.7 per 1000 persons in 2008 (P = .05). However, since 2008, minimum incidence rates for young infants have been rising, with a steep rise from 2.8 per 1000 persons in 2015 to 6.3 per 1000 persons in 2017. For most pathogens, there is an overall decreasing trend in minimum incidence rates (Figure 1) over these 2 decades, with the exception of Salmonella Typhi and Klebsiella spp. For S. Typhi, minimum incidence rates for children ≤5 years increased from a low of 0 per 1000 persons in 2003 to a peak of 1.3 per 1000 persons in 2013, and then declined to 0.3 per 1000 persons in 2017 (overall increasing trend, P = .0016); for Klebsiella spp., minimum incidence rates went from a low of 0.2 per 1000 persons in 2012 to 0.9 per 1000 persons in 2017 (P = .727). However, when
the outlier values for 2016 and 2017 were excluded, there was a declining trend for *Klebsiella* spp. sepsis between 1998 and 2015 (*P* = .009).

**Pathogen Etiology**

During the first period (1998–2002; Table 1), NTS accounted for 41.4% (1644/3964) of pathogenic isolates, followed by *S. pneumoniae* at 10.2% (405/3964) and *S. aureus* and *E. coli* at 6.2% each (247/3964). In the last period (2013–2017), the most common causes of pediatric BSI were *Salmonella Typhi* (544/2614, 20.8%), *Klebsiella* spp. (316/2614, 12.1%, with *K. pneumoniae* comprising 93.7% [295] of these), NTS (303/2614, 11.6%), and *Staphylococcus aureus* (253/2614, 9.7%). *S. pneumoniae* accounted for 1.9% (49/2614) of isolates in the last period. For young-infant BSI in the first period (Supplementary Table 2), the most common causes were NTS (133/835, 15.9%), *S. aureus* (118/835, 14.1%), and Group B Strep (109/835, 13.1%). In the last period, the most common causes were *Klebsiella* spp. (230/800, 28.9%), followed by *S. aureus* (139/800, 17.4%), *Enterobacter* spp. (101/800, 12.6%), *Enterococcus* spp. (72/800,

**Table 1. Bloodstream Infections in Children ≤5 Years at Queen Elizabeth Central Hospital, by Isolate and Period**

| Time Period   | 1998–2002 | 2003–2007 | 2008–2012 | 2013–2017 |
|---------------|-----------|-----------|-----------|-----------|
| **Gram-positives** |           |           |           |           |
| Group A Strep | 96        | 42        | 32        | 29        |
| Group B Strep | 126       | 116       | 39        | 48        |
| *Streptococcus pneumoniae* | 405      | 423       | 166       | 49        |
| *Staphylococcus aureus* | 247      | 283       | 185       | 253       |
| Other *Streptococcus* spp. | 197      | 244       | 193       | 222       |
| *E. faecalis* | 26        | 63        | 38        | 30        |
| *E. faecium* | 0         | 0         | 10        | 69        |
| All *Enterococcus* spp. | 31       | 63        | 50        | 99        |
| Leuconostoc | 0         | 0         | 0         | 0         |
| **Gram-negatives** |           |           |           |           |
| *Acinetobacter baumanii* | 0        | 9         | 17        | 58        |
| All *Acinetobacter* spp. | 86      | 101       | 35        | 59        |
| *Citrobacter* spp. | 37       | 33        | 6         | 7         |
| *Enterobacter* spp. | 57       | 133       | 33        | 132       |
| Escherichia coli | 247      | 282       | 163       | 165       |
| *Haemophilus influenzae* type B | 157    | 44        | 19        | 16        |
| All *Haemophilus* spp. | 178     | 67        | 38        | 26        |
| *Klebsiella pneumoniae* | 57      | 103       | 123       | 295       |
| All *Klebsiella* spp. | 179     | 144       | 132       | 316       |
| *Neisseria meningitidis* | 14      | 18        | 5         | 11        |
| *N. gonorrhoeae* | 0        | 0         | 1         | 6         |
| *Proteus* spp. | 15       | 3         | 2         | 3         |
| *Pseudomonas aeruginosa* | 28      | 47        | 20        | 36        |
| All *Pseudomonas* spp. | 38      | 55        | 33        | 49        |
| *Salmonella typhi* | 8        | 16        | 50        | 544       |
| NTS | 1644 | 1505 | 532 | 303 |
| **Serratia* spp. | 38       | 16        | 4         | 17        |
| *Shigella* spp. | 3        | 4         | 4         | 6         |
| *Vibrio* spp. | 0        | 0         | 2         | 0         |
| *Yersinia* spp. | 2        | 0         | 2         | 0         |
| Other Gram-negatives* | 301      | 412       | 203       | 253       |
| **Fungus** |           |           |           |           |
| *Candida* | 5        | 1         | 4         | 7         |
| *Cryptococcus* | 0        | 0         | 6         | 4         |
| Yeast species | 0        | 0         | 0         | 3         |
| **All pathogens** | 3964 | 3970 | 1923 | 2614 |

Abbreviation: NTS, non-typhoidal *Salmonella*.  
*Includes* *Aeromonas* spp., *Agrobacter* spp., *Burkholderia* spp., *Cronobacter* spp., *Enterobacteriaceae*, *Flavobacteria*, *Gram-negative rods*, *Hafnia* spp., *Hafnia* spp., *Kluyvera* spp., *Moraxella* spp., *Morganella* spp., *Pasteurella* spp., *Pantoea* spp., *Pseudomonas* spp., *Sphingomonas* spp., *Stenotrophomonas* spp., and *Xanthomonas* spp.  
*Excludes* contaminants, including *Aerococcus* spp., *alpha-hemolytic streptococci*, *Alcaligenes* spp., *Bacillus* spp., *Clostridium* spp., *coagulase-negative staphylococci*, *Corynebacteria*, *Diptheroids*, *Gram-positive rods*, *Rhizobium* spp., *Micrococcus* spp., and skin flora.
9%); *E. coli* (57/800, 7.1%), and Group B Strep (43/800, 5.4%). Only 0.6% (5/800) of *S. pneumoniae* specimens were isolated from young infants in the last period, compared to 6.2% (52/835) in the first.

**Antimicrobial Resistance Profiles**

For Gram-positive pathogens, resistance to empiric, first-line antimicrobials—ampicillin/penicillin with gentamicin, or ceftriaxone—was 21.1% (605/2863) and 6.2% (74/1199) of isolates, respectively. For Gram-negative pathogens, the proportion of culture-confirmed BSI among children ≤5 years that were resistant to all first-line antimicrobials had an overall increasing trend over time, from 3.4% (8/235) in the first period to 30.2% (449/1487) in the last period (*P* < .001; Figure 2). For young infants, the overall proportion of Gram-negative bacteria resistant to all first-line antimicrobials increased from 7.0% (3/43) in the first period to 67.7% (315/465) in the last (*P* < .001).

For Gram-positive pathogens, penicillin resistance (including intermediate susceptibility) in *S. pneumoniae* did not increase significantly during the study period (*P* = .210; Table 2). Methicillin-resistant *Staphylococcus aureus* isolates increased from 0% (0/247) to 2.7% (6/224), which was not significant (*P* = .09). *Enterococcus* spp. resistance to ampicillin increased from 11.1% (1/9) in the first period to 69.7% (69/99) in the last (*P* < .001), which could be attributed to the 7-fold increase in *E. faecium* spp. isolated, concurrent with a relative decrease in *E. faecalis* over the same period.

For Gram-negative pathogens, excluding Salmonellae, an increase in resistance to ceftriaxone and gentamicin to over 60% during the study period was documented (Figure 3). *E. coli*’s resistance to ceftriaxone increased from 11.1% (4/36) in the first period to 28.5% (47/165) in the last (*P* < .001), while its resistance to gentamicin increased from 19.7% (48/244) in the first period to 32.7% (54/165) in the last (*P* < .001), and its resistance to ampicillin remained unchanged and had a mean annual rate of 89.7% throughout the study period (*P* = .466).

For *Klebsiella* spp., ceftriaxone resistance rose from 21.1% (4/19) in the first period to 90.5% (286/316) in the last (overall increasing trend, *P* < .001), whereas gentamicin resistance rose from 38.2% (68/178) in the first period to 90.7% (282/311) in the last (overall increasing trend, *P* < .001). Resistance to ciprofloxacin for both pathogens was also observed to steadily increase during the entire 2 decades, from 0% (0/113) in the first period to 26.0% (43/165) in the last (*P* < .001) in *E. coli* and from 0% (0/73) to 34.5% (109/316) for *Klebsiella* spp (*P* < .001). Resistance to all empiric, first-line antimicrobials for *E. coli* was over 20% (Figure 3) and there was an overall increasing trend in the proportion of *Klebsiella* spp. resistant to all first-line antimicrobial regimens over time, from 5.9% (1/17) to 93.7% (133/142; *P* < .001). Both *S. Typhi* and NTS had infrequent resistances to ceftriaxone (0/566 and 8/1980) and ciprofloxacin (1/610 and 10/3392) throughout all periods. We have not detected ESBL NTS BSI in children [18]. A similar trend in AMR profiles was also noted for young infants (Supplementary Table 3).

**DISCUSSION**

Over the past 2 decades, overall, the incidence of BSI in hospitalized children at QECH, the largest teaching hospital in Malawi, has decreased. This includes NTS, for which no vaccine was available during the study period, and *H. influenzae* type B and *S. pneumoniae*, for which vaccination programs were introduced during the study period (in 2002 and 2011, respectively). However, in the last 10 years, the incidence of young infant BSI caused by *S. Typhi* and *Klebsiella* spp. in those under 5 has risen considerably. We have previously reported 3 epidemics of *Salmonella*, which appear to have arisen through the acquisition of virulence and AMR determinants in the context of a susceptible population [19–22]. Gram-positive pathogens are still largely susceptible to first-line antimicrobials, with the exception of *Enterococcus* spp. and *E. faecium*, which, as an emerging pathogen, needs ongoing surveillance. For Gram-negative BSI among children ≤5 years, the proportion of bacteria that are resistant to empiric, first-line antimicrobials is high, rising, and most marked among young infants. These findings reveal the growing problem of AMR in our setting and emphasize the need for robust antimicrobial stewardship programs and ongoing surveillance, even when BSI overall appears to be declining.

The rise in the number of Gram-negative pathogens resistant to first-line antimicrobials, specifically *Klebsiella* spp., contrasts with earlier data from our institution, where isolates had high susceptibility (78%) [23]. One reason for the rise in
### Table 2. Antimicrobial Resistance Profiles of Selected Bloodstream Pathogens for Children ≤5 Years, by Period

| Pathogen                  | Time Period | Ampicillin | Penicillin | Ceftiraxone | Chloramphenicol | Gentamicin | Co-trimoxazole | Ciprofloxacin |
|---------------------------|-------------|------------|------------|-------------|-----------------|------------|----------------|--------------|
| S. pneumoniae             | 1998–2002   | NT         | 91/ 134    | 24.3        | 0/ 50           | 0/ 362     | 15.0           | 314/ 364     | 82.3         | NT           |
|                           | 2003–2007   | NT         | 73/ 420    | 17.4        | 0/ 421          | 0/ 72       | 17.2           | 387/ 411     | 94.2         | NT           |
|                           | 2008–2012   | NT         | 29/ 164    | 17.7        | 0/ 166          | 21/ 164     | 17.7           | 153/ 166     | 92.3         | NT           |
|                           | 2013–2017   | NT         | 15/ 49     | 30.6        | 0/ 48           | 0/ 154     | 30.6           | 48/49        | 93.9         | NT           |
| S. aureus<sup>b</sup>     | 1998–2002   | NT         | 227/ 245   | 92.7        | NT              | 97/ 241    | 40.2           | NT           | 127/ 244     | 52.0         |
|                           | 2003–2007   | NT         | 245/ 262   | 93.5        | NT              | 85/ 269    | 31.6           | NT           | 137/ 265     | 51.7         |
|                           | 2008–2012   | NT         | 47/ 57     | 82.5        | NT              | 29/ 181    | 16.0           | NT           | 78/ 180      | 43.3         |
| Enterococcus spp.         | 1998–2002   | NT         | 1/ 9       | 11.1        | NT              | 14/ 30     | 46.7           | NT           | 20/ 22       | 90.9         |
|                           | 2003–2007   | NT         | 5/ 44      | 11.4        | NT              | 38/ 62     | 61.3           | NT           | 100/ 61      | 54.1         |
|                           | 2008–2012   | NT         | 17/ 38     | 44.7        | NT              | 33/ 47     | 70.2           | NT           | 40/ 44       | 90.9         |
| Klebsiella spp.           | 1998–2002   | NT         | 178/ 178   | 100         | NT              | 13/ 177    | 78.5           | NT           | 149/ 176     | 84.7         |
| Enterobacter spp.         | 1998–2002   | NT         | 55/ 83     | 66.3        | NT              | 32/ 84     | 46.4           | NT           | 36/ 64       | 53.6         |
| Pseudomonas spp.          | 1998–2002   | NT         | 10/ 14     | 71.4        | NT              | 8/ 12      | 66.7           | NT           | 10/ 15       | 66.7         |
| Salmonella Typhi           | 1998–2002   | NT         | 4/ 7       | 57.1        | NT              | 0/ 3       | 42.9           | NT           | 4/ 7         | 57.1         |
| NT                        | 2003–2007   | NT         | 2/ 16      | 12.5        | NT              | 0/ 16      | 0              | NT           | 100/ 16      | 6.9          |
|                           | 2008–2012   | NT         | 37/ 50     | 74           | NT              | 0/ 50      | 74             | NT           | 35/ 50       | 70           |
| Other Enterobacteriaceae<sup>a</sup> | 1998–2002   | NT         | 5/ 9       | 85.9        | NT              | 6/ 55      | 40.2           | NT           | 36/ 72       | 52.7         |
| Other Gram-negative<sup>a</sup> | 1998–2002   | NT         | 105/ 145   | 72.4        | 0/ 12          | 4/ 123     | 3.3            | NT           | 100/ 145     | 89.2         |
|                           | 2003–2007   | NT         | 54/ 93     | 58.1        | 4/ 23          | 14/ 121    | 0.3            | NT           | 85/ 138      | 56.6         |
|                           | 2008–2012   | NT         | 52/ 76     | 68.4        | 5/ 7           | 18/ 109    | 16.5           | NT           | 85/ 109      | 78.0         |
|                           | 2013–2017   | NT         | 44/ 52     | 84.6        | 4/ 9           | 25/ 75     | 33.3           | NT           | 44/ 50       | 76.1         |

**Abbreviations:** NT, not tested; NTS, nontyphoidal Salmonella.

<sup>a</sup>Pneumococcal isolates initially reported as ceftiraxone-resistant were re-tested and found to be susceptible. Based on these, isolates not available for re-testing (99) were considered susceptible.

<sup>b</sup>Methicillin-resistant Staphylococcus aureus isolates for these periods were: 1998–2002, 0 (0%); 2003–2007, 12 (0.3%); 2008–2012, 20 (1.3%); and 2013–2017, 35 (1.3%).

<sup>c</sup>Note that gentamicin should not be used alone for S. aureus, even if susceptible.

<sup>d</sup>All Enterobacter isolates have been reported resistant to ceftriaxone, in line with British Society of Antimicrobial Chemotherapy (BSAC) guidance.

<sup>e</sup>All Pseudomonas isolates have been reported not tested, as these pathogens are intrinsically resistant to ampicillin, chloramphenicol, and co-trimoxazole.

<sup>f</sup>All Salmonella isolates have been reported resistant to gentamicin, in line with BSAC guidance.

<sup>g</sup>Includes Citrobacter spp., Coliforms, Cronobacter spp., Escherichia spp., Hafnia spp., Kuyvera spp., Morganella spp., Pantoea spp., Proteus spp., Raoultella spp., Seratia spp., Shigella spp., and Yersinia spp.

<sup>h</sup>Includes Aeromonas spp., Burkhodella spp., Edwardsiella spp., Flavobacteria, Gram-negative rods, Haemophilus spp., Histophilus spp., Moraxella spp., Neisseria spp., Pasteurella spp., Sphingomonas spp., Stenotrophomonas spp., Vibrio spp., and Xanthomonas spp.
AMR could be attributed to a marked increase in the use of broad-spectrum antimicrobials in recent years [24], including among neonates. *Klebsiella* spp. isolates recovered within the first 3 days of birth accounted for 28.4% (84/295) of all pediatric *Klebsiella* spp. specimens in the last period, suggesting high rates of vertical transmission. The reasons for increases in rates of AMR *Klebsiella* spp. are not certain, since there have been no changes in practices in the neonatal unit that we can identify. The increase may have been amplified by an increased transmission capacity, resulting in outbreaks in neonatal units [25, 26]. The high ESBL carriage in children <5 years [27] may have also contributed to horizontal transmission. Community-based surveillance of both the disease and carriage is ongoing [28] to explore whether increasing rates of AMR may be related to the strengthening of primary healthcare systems following the model of IMCI and earlier treatment with antimicrobials, and may thereby be limited to the hospital setting.

Alternative antimicrobials for Gram-negative pathogens in these settings could include the use of amikacin, where resistance rates are much lower than gentamicin (6.3% compared to 66.0%, respectively); or ciprofloxacin, where resistance rates are already rising, although, when used in children, this has to be weighed against the side effects of tendinopathy. The inclusion of meropenem on the Malawi national formulary in 2015 and its availability in hospitals may be beneficial in the short term, but increased use is likely to drive further AMR, similar to the increase in ESBL organisms seen following ceftriaxone use. This would be in a setting where there are limited diagnostic facilities and where antimicrobial stewardship initiatives are beset by scarce resources.

Limitations to this study include that these are urban, tertiary, referral, hospital-based data from a single site, and not national surveillance. However, such large-scale, long-term, routine surveillance data is rarely available in this setting at a national level. Hospital-based surveillance could have impacted the rates of AMR, as susceptible BSI may have responded to empiric oral antibiotics in the community, and only the sickest children present to the hospital. However, given the likely clinical severity of BSI, except for in children with typhoid fever, and the absence of other pediatric inpatient facilities, this bias is unlikely to be substantial. We could not reliably differentiate community- from hospital-acquired BSI, which could be particularly relevant to young-infant BSI, where some neonates have prolonged stays and have follow-up blood cultures obtained prior to changes in antimicrobial regimens for presumed sepsis. Nosocomial BSI may have contributed to our relatively high recovery rate of 11.9%, but many of the prominent pathogens are uncommonly associated with nosocomial transmission. As blood cultures are not routinely repeated if the bacteria that are considered contaminants are isolated, we may have underestimated the number of true pathogens; however, typical risk factors, such as indwelling vascular devices or febrile neutropenia, are extremely rare in this population and prematurity would not have accounted for a substantial proportion. ESBL screening was not introduced until 2003; therefore, ESBL-producing pathogens may have been circulating yet undetected before then. Changes made to breakpoints in subsequent British Society of Antimicrobial Chemotherapy versions would have led to a wider use of “intermediate” categories that, in our study, may have increased the number of Gram-negative pathogens regarded as resistant. In all pediatric BSI surveillance studies, the available blood volumes for culture remain a challenge and, therefore, underestimates of pathogens such as *S. pneumoniae* and *S. Typhi* are possible, particularly in infants. Comprehensive clinical data was not available to evaluate the contribution of AMR to mortality; however, we have previously reported the mortality associated with specific pathogens [29–32].

Our results raise significant concerns about the growing issue of AMR, and highlight the urgent need to review empiric, antimicrobial regimens; implement and enforce infection control practices; and undertake pragmatic trials of antimicrobial stewardship. However, in many LMICs, without local data, it remains challenging to adapt the WHO IMCI guidelines to reflect local needs [5]. While awaiting both the impact of international

---

Figure 3. Proportion of non-Salmonella, Gram-negative isolates with: (A) Gentamicin- or ceftriaxone-resistance, for children ≤5 years; or (B) *E. coli* and *Klebsiella* spp. resistance to empiric first-line antimicrobials, for children ≤5 years. First-line antimicrobials in Malawi are ampicillin/penicillin with gentamicin, or ceftriaxone.
initiatives to expand access to high-quality laboratory surveillance [33, 34] and the development of rapid diagnostics [35, 36], there should be a considerable emphasis on expanded access to effective antimicrobials in the context of locally-relevant antimicrobial stewardship programs. These should include the education of community- and hospital-based healthcare providers on prescribing practices, the epidemiology of infections, when not to prescribe antibiotics, the development of and adherence to guidelines on de-escalation and cessation of antimicrobial therapy, and infection control practices. The development of pragmatic clinical trials to evaluate new antimicrobial strategies in young children should be a priority.

**Supplementary Data**

Supplementary materials are available at Clinical Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyrighted and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

**Notes**

**Acknowledgments.** The authors thank the clinical and support staff at Queen Elizabeth Central Hospital. They thank Todd Swarthout and Jacqueline Chinkwita for assistance with antimicrobial susceptibility re-testing of pneumococcal isolates. They thank Franziska Olgemoeller for collecting pediatric antibiogram data. They thank Clemens Masesa and Moses Kamzazi for extraction of blood culture data.

**Financial support.** This work was supported by the Wellcome Trust; National Institutes of Health through the H3ABionet Project (grant number U41HG006941 to D. E.); and the Southern Africa Consortium for Research Excellence.

**Potential conflicts of interest.** N. French reports grants from GlaxoSmithKline, outside the submitted work. P. I. reports grants from the Bill and Melinda Gates Foundation, outside the submitted work. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

**References**

1. UNICEF. One is too many: ending child deaths from pneumonia and diarrhoea. New York: United Nations Children’s Fund. 2016.

2. Swann O, Everett DB, Furry JS, et al. Bacterial meningitis in Malawian infants <2 months of age: etiology and susceptibility to World Health Organization first-line antibiotics. Pediatr Infect Dis J 2014; 33:560–5.

3. Molyneux EM, Dube Q, Bande FM, et al. The treatment of possible severe infection in infants: an open randomized safety trial of parenteral benzylpenicillin and gentamicin versus ceftriaxone in infants <60 days of age in Malawi. Pediatr Infect Dis J 2017; 36:e328–33.

4. World Health Organization. Integrated management of childhood illness chart booklet. Geneva, Switzerland: World Health Organization, 2014.

5. Fleschmann-Struzek C, Goldfarb DM, Schlattmann P, Schlapbach LJ, Reinhart K, Kussoo N. The global burden of paediatric and neonatal sepsis: a systematic review. Lancet Respir Med 2018; 6:223–30.

6. Daza P, Bande R, Misoya K, et al. The impact of routine infant immunization with Haemophilus influenzae type b conjugate vaccine in Malawi, a country with high human immunodeficiency virus prevalence. Vaccine 2006; 24:6232–9.

7. Government of Malawi Ministry of Health. Integrated HIV program report July-September 2016. Lilongwe, Malawi: Government of Malawi Ministry of Health, 2016.

8. World Health Organization. Malawi maternal and child health data. Geneva, Switzerland: World Health Organization, 2015.

9. Jahn A, Floyd S, Crampin AC, et al. Declining child mortality in northern Malawi despite high rates of infection with HIV. Bull World Health Organ 2010; 88:746–53.

10. Mwagomba B, Zachariah R, Massaquoi M, et al. Mortality reduction associated with HIV/AIDS care and antiretroviral treatment in rural Malawi: evidence from registers, coffin sales and funerals. PLoS One 2010; 5:e10452.

11. Zimba E, Kinney MV, Kachale F, et al. Newborn survival in Malawi: a decade of change and future implications. Health Policy Plan 2012; 27(Suppl 3):i88–103.

12. Musicha P, Cornick JE, Bar-Zeev N, et al. Trends in antimicrobial resistance in bloodstream infection isolates at a large urban hospital in Malawi (1998–2016): a surveillance study. Lancet Infect Dis 2017; 17:1042–52.

13. World Health Organization. Antimicrobial resistance: global report on surveillance. Geneva, Switzerland: World Health Organization, 2014.

14. Senn N, Rauz P, Salih M, et al. Use of antibiotics within the IMCI guidelines in outpatient settings in Papua New Guinean children: an observational and effectiveness study. PLoS One 2014; 9:e99990.

15. Zurovac D, Rowe AK. Quality of treatment for febrile illness among children at outpatient facilities in sub-Saharan Africa. Ann Trop Med Parasitol 2006; 100:285–96.

16. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. Chest 1992; 101:1644–55.

17. Gordon MA, Walsh AL, Chaponda M, et al. Bacteremia and mortality among adult medical admissions in Malawi: predominance of non-typhi salmonellae and Streptococcus pneumoniae. J Infect 2001; 42:44–9.

18. Feasey NA, Cain AK, Msefula CL, et al. Drug resistance in Salmonella enterica ser. Typhimurium bloodstream infection, Malawi. Emerg Infect Dis 2014; 20:1957–9.

19. Feasey NA, Gaskell K, Wong V, et al. Rapid emergence of multidrug resistant, H58-lineage Salmonella typhi in Blantyre, Malawi. PLoS Negl Trop Dis 2015; 9:e0003748.

20. Feasey NA, Hadfield J, Keddy KH, et al. Distinct Salmonella enteritidis lines associated with enterocolitis in high-income settings and invasive disease in low-income settings. Nat Genet 2016; 48:1211–7.

21. Gordon MA, Graham SM, Walsh AL, et al. Epidemics of invasive Salmonella enterica serovar enteritidis and S. enterica Serovar typhimurium infection associated with multidrug resistance among adults and children in Malawi. Clin Infect Dis 2008; 46:963–9.

22. Kingsley RA, Msefula CL, Thomson NR, et al. Epidemic multiple drug resistant Salmonella Typhimurium causing invasive disease in sub-Saharan Africa have a distinct genotype. Genome Res 2009; 19:2279–87.

23. Milledge J, Calis JC, Graham SM, et al. Aetiology of neonatal sepsis in Blantyre, Malawi: 1996–2001. Ann Trop Paediatr 2005; 25:101–10.

24. Feasey NA, Houston A, Mukaka M, et al. A reduction in adult blood stream infection and case fatality at a large African hospital following antiretroviral therapy roll-out. PLoS One 2014; 9:e92226.

25. Gurtева T, Dautzenberg MJD, Gniadkowski M, Derde LPG, Bonten MJM, Boosten MMCJ. The transmissibility of antibiotic-resistant Enterobacteriaceae in intensive care units. Clin Infect Dis 2018; 66:489–93.

26. Hilty M, Betsch BY, Bogli-Stuber K, et al. Transmission dynamics of extended-spectrum β-lactamase-producing Enterobacteriaceae in the tertiary care hospital and the household setting. Clin Infect Dis 2012; 55:967–75.

27. Schaumburg F, Alabi A, Kokou C, et al. High burden of extended spectrum β-lactamase-producing Enterobacteriaceae in Gabon. J Antimicrob Chemother 2013; 68:2140–9.

28. Darton TC, Meiring JE, Tonks S, et al. STRATAA Study Consortium. The STRATAA study protocol: a programme to assess the burden of enteric fever in Bangladesh, Malawi and Nepal using prospective population censuses, passive surveillance, serological studies and healthcare utilisation surveys. BMJ Open 2017; 7:e016283.

29. Fox-Lewis A, Takata J, Miliya T, et al. Antimicrobial resistance in invasive bacterial infections in hospitalized children, Cambodia, 2007–2016. Emerg Infect Dis 2018; 24:841–51.

30. Kayange N, Kamugisha E, Mwizambyala DL, Jeremia S, Mshana SE. Predictors of positive blood culture and deaths among neonates with suspected neonatal sepsis in a tertiary hospital, Mwanza-Tanzania. BMC Pediatr 2010; 10:39.

31. Laxminarayan R, Bhatta ZA. Antimicrobial resistance: a threat to neonatal survival. Lancet Glob Health 2016; 4:e676–7.

32. Thaver D, Ali SA, Zaidi AK. Antimicrobial resistance among neonatal pathogens in developing countries. Pediatr Infect Dis J 2009; 28:S19–21.

33. WHO. Guide for establishing laboratory-based surveillance for antimicrobial resistance. Available at: http://apps.who.int/medicinedocs/documents/s20135en/s20135en.pdf. Accessed 30 April 2018.

34. World Bank. AFCCC/RI-East Africa public health laboratory networking project. Available at: http://projects.worldbank.org/P111556/east-africa-public-health-laboratory-networking-project/lang=en. Accessed 30 April 2018.

35. Amukute T, Africa CDC: establishing integrated surveillance and laboratory networks for rapid disease detection and response, control, prevention, and clinical care in Africa. Afr J Lab Med 2017; 6:638.

36. Peeling RW, Mahey D. Point-of-care tests for diagnosing infections in the developing world. Clin Microbiol Infect 2010; 16:1062–9.